enGene Therapeutics Inc.
corporate_fare Company Profile
enGene Therapeutics Inc. (NASDAQ:ENGN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for ENGN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ENGN spans 8-K, 8-K/A, 10-Q, 424B5.
Recent high-impact activity:
- Bladder Cancer Data Update Lifts Shares ~20%; Piper Upgrades to Overweight
- enGene's LEGEND Cohort 1 CR Rises to 56%, BLA Filing Set for Q4 2026
- Bladder Cancer Data Improves Across Key Endpoints, BLA Filing Planned
- enGene Q3 Loss Narrows to $0.47/Share; BLA Filing for Detalimogene on Track for 4Q 2026
- enGene Posts Q3 Loss, Sets BLA Filing for Detalimogene in Q4
Financial Snapshot
Short Interest & Short Volume
1.92 days to coverFINRA reported short interest of 1,623,750 shares in ENGN as of the October 30, 2026 settlement, a 8.1% increase from the prior period — about 1.9 days to cover at its recent average daily volume. On November 20, 2026, 50.0% of ENGN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.